Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene

Journal of the National Cancer Institute

Volumn 97, Issue 15, 2005, Pages 1124-1132

  Chen, Wei Dong ^a   Han, Z James ^b   Skoletsky, Joel ^a   Olson, Jeff ^b   Sah, Jerome ^b   Myeroff, Lois ^a   Platzer, Petra ^a   Lu, Shilong ^a   Dawson, Dawn ^c   Willis, Joseph ^c   Pretlow, Theresa P ^c   Lutterbaugh, James ^a   Kasturi, Lakshmi ^a   Willson, James K V ^a   Rao, J Sunil ^a   Shuber, Anthony ^b   Markowitz, Sanford D ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Exact Sciences Corporation   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR MARKER; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; EXON; FECES ANALYSIS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC SCREENING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; ADENOCARCINOMA; ADENOMA; CASE CONTROL STUDY; CELL TRANSFORMATION; CHEMISTRY; COLORECTAL TUMOR; FECES; GENETICS; OCCULT BLOOD; REPRODUCIBILITY;

ADENOCARCINOMA; ADENOMA; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; FECES; HUMANS; OCCULT BLOOD; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 23244439221     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dji204     Document Type: Article

References (32)

1. Baylin S. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 2002;12:331-7.
2. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7.
3. Laird PW. The power and the promise of DNA methylation makers. Nat Rev Cancer 2003;3:253-66.
4. Issa JP. The epigenetics of colorectal cancer. Ann N Y Acad Sci 2000; 910:140-53; discussion 153-5.
5. Veigl M, Kasturi L, Olechnowicz J, Ma A, Lutterbaugh J, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998;95:8698-702.
6. Moinova HR. Chen WD, Shen L, Smiraglia D. Olechnowicz J, Ravi L. et al. HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A 2002;99:4562-7.
7. Li H, Myeroff L, Smiraglia D, Romero MF, Preflow TP, Lakshmi Kasturi L, et al. SLC5A8: A novel sodium transporter, is a tumor suppressor gene silenced by methylation in human colonic aberrant crypt foci and colon cancers. Proc Natl Acad Sci USA 2003;100:8412-7.
8. Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Ziff M, et al. Methylation changes in faecal DNA: A marker for colorectal cancer screening? Lancet 2004;363:1283-5.
9. Deenadayalu VP, Rex DK. Fecal-based DNA assays: A new, noninvasive approach to colorectal cancer screening. Cleve Clin J Med 2004;71: 497-503.
10. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res 2001;61:900-2.
11. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransk D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
12. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, ct al. Gene promoter hypermethylation in rumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
13. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al, Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
14. Markowitz S, Dawson DM, Willis J, Willson JK. Focus on colon cancer. Cancer Cell 2002;1:233-6.
15. Lodish H, Baltimore D, Berk A, Zipursky SL, Mastudaira P, Darnell J, Molecular cell biology. 3rd ed. New York NY: Scientific American Books; 1995.
16. Willson J, Bittner G, Oberley T, Meisner G, Weese J. Cell culture of human colon adenomas and carcinomas. Cancer kes 1987;47:2704-13.
17. Markowitz S, Wang J, Mycroff L, Parsons R, Sun L, Lutterbaugh J. et al. Inactivation ofthe type II TGF-b receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
18. Herman J, Graff J, Myohanen S, Nelkin B, Baylin S. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
19. Whitney D. Skoletsky J, Moore K, Boynton K, Kann L, Brand R, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn 2004;6: 386-95.
20. Harrell F. Regression modeling strategies: With applications to linear modeling, logistic regression and survival analysis. New York NY: Springer: 2001.
21. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, et al. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa, Cancer Res 1991;51:1564-7.
22. Smith RA, Cokkinides V, von Eschcnbach AC, Levin B, Cohen C, Runowicz CD, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002;52:8-22.
23. Winawer S. Fletcher R. Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: Clinical guidelines and rationale- Update based on new evidence. Gastroenterology 2003;124:544-60.
24. Vernon SW. Participation in colorectal cancer screening: A review. J Natl Cancer Inst 1997;89:1406-22,
25. Imperiable TF. Ransohoff DF. Itzkowitz SH, Turnbull BA. Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an avarage-risk population. N Engl J Med 2004;351:2704-14.
26. Sidransky D, Tokino T, Hamilton S, Kinzler K, Levin B. Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
27. Ahlquist DA. Shuber AP. Stool screening for colorectal cancer: Evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-68.
28. Traverso G, Shuber A, Levi B, Johnson C, Olsson L, Schoetz DJ Jr, et al. Derection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
29. Traverso G, Shuber A, Olsson L, Levin B, Johnson C, Hamilton SR. et al. Derection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002;359:403-4.
30. Ahlquist DA. Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierccall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
31. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.
32. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003;49:1058-65.